Recent Publications
Zahavi DJ, Erbe R, Zhang YW, Guo T, Malchiodi ZX, Maynard RM, Lekan A, Gallagher R, Wulfkuhle J, Petricoin E, Jablonski SA, Fertig EJ & Weiner LM. Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. Cancer Biol Ther, 2023 24:1, DOI: 10.1080/15384047.2023.2269637
Weinberg BA, Wang H, Noel MS, He AR, Marshall JL, Weiner LM, Fishbein TM, Hodgins NE, Winslow ER, Jackson PG, Guerra JF, Aguila F, Unger KR. Phase I Study of Hypofractionated Proton Beam Radiotherapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Int J Radiat Oncol Biol Phys. 2023 Sep 15:S0360-3016(23)07927-0. doi: 10.1016/j.ijrobp.2023.09.015. Online ahead of print.
Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Discov. 2023 Sep 13:OF1-OF4. doi: 10.1158/2159-8290.CD-23-0988. Online ahead of print. PMID: 37702762
Fitzgerald, A, Maynard R, Zahavi D, and Weiner LM. (2023). Chapter 17: Immunotherapy Agents: Monoclonal Antibodies. In VT DeVita Jr, TS Lawrence, SA Rosenberg (Eds.). DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition. Philadelphia, PA. Wolters Kluwer.
Kemeny MM, Zhao F, Forastiere AA, Catalano P, Hamilton SR, Miedema BW, Dawson NA, Weiner LM, Smith BD, Mason BA, Graziano SL, Gilman PB, Venook AP, Pinto HA, Whitehead RP, O'Dwyer PJ, Benson AB. Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292). Ann Surg Oncol. 2023 Feb;30(2):1099-1109. doi: 10.1245/s10434-022-12705-8. Epub 2022 Oct 28. PMID: 36305992
Moscarelli J, Zahavi D, Maynard R, Weiner LM. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells. Transplant Cell Ther. 2022 Jul 3:S2666-6367(22)01435-X. doi:10.1016/j.jtct.2022.06.025. Online ahead of print.PMID: 35788086
Maeng HM, Moore BN, Bagheri H, Steinberg SM, Inglefield J, Dunham K, Wei WZ, Morris JC, Terabe M, England LC, Roberson B, Rosing D, Sachdev V, Pack SD, Miettinen MM, Barr FG, Weiner LM, Panch S, Stroncek DF, Wood LV, Berzofsky JA. Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. Front Oncol. 2021 Dec 16;11:789078. doi: 10.3389/fonc.2021.789078. eCollection 2021. PMID: 34976830
Fitzgerald AA, Wang S, Agarwal V, Marcisak EF, Zuo A, Jablonski SA, Loth M, Fertig EJ, MacDougall J, Zhukovsky E, Trivedi S, Bhatia D, O'Neill V, Weiner LM. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2021 Nov;9(11):e002837. doi: 10.1136/jitc-2021-002837.
PMID: 34737215
Davis-Marcisak EF, Fitzgerald AA, Kessler MD, Danilova L, Jaffee EM, Zaidi N, Weiner LM, Fertig EJ.
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. Genome Med. 2021 Aug 11;13(1):129. doi: 10.1186/s13073-021-00944-5. PMID: 34376232
Gerson SL, Shaw K, Harrison LB, Holcombe RF, Hutchins L, Lee CB, Loehrer PJ, Mulkerin D, Purcell WT, Teston L, Weiner LM, Weiner GJ. Status of Cancer Care at Network Sites of the Nation's Academic Cancer Centers. J Natl Compr Canc Netw. 2021 Mar 11:1-7. doi: 10.6004/jnccn.2020.7656. Online ahead of print. PMID: 33706258
Fitzgerald AA, Marcisak EF, Nasir A, Glasgow E, Jablonski SA, Van Der Veken P, Pearson G, Fertig EJ, Mace EM, Weiner LM. Fibroblast activation protein regulates natural killer cell migration, extravasation and tumor infiltration. BioRXiv. doi: https://doi.org/10.1101/2021.02.03.429622
Malchiodi ZX, Weiner LM. Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021 Jan 22;13(3):405. doi: 10.3390/cancers13030405. PMID: 33499238
Ajina R, Malchiodi ZX, Fitzgerald AA, Zuo A, Wang S, Moussa M, Cooper CJ, Shen Y, Johnson QR, Parks JM, Smith JC, Catalfamo M, Fertig EJ, Jablonski SA, Weiner LM. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. Cancer Immunol Res. 2021 Jan 28:canimm.0272.2020. doi: 10.1158/2326-6066.CIR-20-0272. Online ahead of print. PMID: 33509790
Peran I, Dakshanamurthy S, McCoy MD, Mavropoulos A, Allo B, Sebastian A, Hum NR, Sprague SC, Martin KA, Pishvaian MJ, Vietsch EE, Wellstein A, Atkins MB, Weiner LM, Quong AA, Loots GG, Yoo SS, Assefnia S, Byers SW. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Gastroenterology. 2020 Dec 9:S0016-5085(20)35513-X. doi: 10.1053/j.gastro.2020.11.044. Online ahead of print. PMID: 33307028
Fitzgerald AA, Li E, Weiner LM. 3D Culture Systems for Exploring Cancer Immunology. Cancers (Basel). 2020 Dec 28;13(1):56. doi: 10.3390/cancers13010056. PMID: 33379189
Aranha MP, Jewel YSM, Beckman RA, Weiner LM, Mitchell JC, Parks JM, Smith JC. Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding Predictions. J Immunol. 2020 Oct 1;205(7):1962-1977. doi: 10.4049/jimmunol.1900918. Epub 2020 Sep 2. PMID: 32878910
Ajina R, Weiner LM. T-Cell Immunity in Pancreatic Cancer. Pancreas. 2020 Sep;49(8):1014-1023. doi: 10.1097/MPA.0000000000001621. PMID: 32833941
Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Jul 15:clincanres.1301.2020. doi: 10.1158/1078-0432.CCR-20-1301. Online ahead of print. PMID: 32669374
Zahavi D. Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies 2020, 9, 34.
Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020 Jun 29. doi: 10.1007/s10555-020-09909-3. Online ahead of print.PMID: 32601975 Review.
Ajina R, Zuo A, WangS, Moussa M, Cooper CJ, Shen Y, Johnson QR, Parks JM, Smith JC, Catalfamo M, Fertig EJ, Jablonski SA, Weiner LM. Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion. bioRxiv 2020.06.15.151274; doi: https://doi.org/10.1101/2020.06.15.151274.
Davis-Marcisak, EF, Fitzgerald AA, Kessler MD, Danilova L, Jaffee EM, Zaidi N, Weiner LM, Fertig EJ. A novel mechanism of natural killer cell response to anti-CTLA-4 therapy identified by integrative analysis of mouse and human tumors. bioRxiv 2020.05.31.125625; doi: https://doi.org/10.1101/2020.05.31.125625.
Ajina R, Zahavi DJ, Zhang YW, Weiner LM. Overcoming Malignant Cell-Based Mechanisms of Resistance to Immune Checkpoint Blockade Antibodies. Semin Cancer Biol. 2019 Dec 19. pii: S1044-579X(19)30401-8. doi: 10.1016/j.semcancer.2019.12.005. [Epub ahead of print] Review. PMID: 31866479.
Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, Kim C, Weiner LM. Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. J Cancer Surviv. 2019 Nov 4. doi: 10.1007/s11764-019-00826-1. [Epub ahead of print]. PMID: 31686365.
Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack. Methods Enzymol. 2020;636:299-322. doi: 10.1016/bs.mie.2019.06.002. Epub 2019 Jul 3. PMID: 32178823
Zahavi DJ, Weiner LM. Tumor mechanisms of resistance to immune attack. Prog Mol Biol Transl Sci. 2019;164:61-100. doi: 10.1016/bs.pmbts.2019.03.009. Epub 2019 Apr 3. PMID: 31383409.
Sherman TD, Kagohara LT, Cao R, Cheng R, Satriano M, Considine M, Krigsfeld G, Ranaweera R, Tang Y, Jablonski SA, Stein-O'Brien G, Gaykalova DA, Weiner LM, Chung CH, Fertig EJ. CancerInSilico: An R/Bioconductor package for combining mathematical and statistical modeling to simulate time course bulk and single cell gene expression data in cancer. PLoS Comput Biol. 2019 Apr 19;14(4):e1006935. doi: 10.1371/journal.pcbi.1006935. eCollection 2018 Jun. PMID: 31002670.
Ajina R, Zamalin D, Zuo A, Moussa M, Catalfamo M, Jablonski SA, Weiner LM. SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice, OncoImmunology (2019), 8:5, DOI: 10.1080/2162402X.2019.1577127
Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang Y, O'Connell A, Ma J, Jablonski SA, Weiner LM. A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res. 2018 Dec 18. pii: canimm.0266.2018. doi: 10.1158/2326-6066.CIR-18-0266. [Epub ahead of print] PMID:30563830.
Zahavi DJ, Weiner LM. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. Int J Mol Sci. 2019 Jan 4;20(1). pii: E158. doi: 10.3390/ijms20010158. Review.PMID:30621125.
Ajina R, Zamalin D, Weiner LM. Functional genomics: paving the way for more successful cancer immunotherapy. Brief Funct Genomics. 2018 May 11. doi:10.1093/bfgp/ely017. [Epub ahead of print] PubMed PMID: 29762641.
Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett. 2018 May 7. pii: S0304-3835(18)30328-8. doi:10.1016/j.canlet.2018.05.009. [Epub ahead of print] PubMed PMID: 29746929.
Yuan H, Wang X, Shi C, Jin L, Hu J, Zhang A, Li J, Vijayendra N, Doodala V, Weiss S, Tang Y, Weiner LM, Glazer RI. Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis. Sci Rep. 2018 Apr 9;8(1):5717. doi: 10.1038/s41598-018-24022-w. PubMed PMID: 29632317; PubMed Central PMCID: PMC5890253.
Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 2018 Mar 26. doi: 10.1002/cncr.31309. [Epub ahead of print] PubMed PMID: 29579325.
Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi:10.1007/s00280-018-3533-8. Epub 2018 Feb 1. PubMed PMID: 29392450.
Shuptrine CW, Ajina R, Fertig EJ, Jablonski SA, Lyerly HK, Hartman ZC, Weiner LM. "An Unbiased In Vivo Functional Genomics Screening Approach In Mice Identifies Novel Tumor Cell-based Regulators Of Immune Rejection." Cancer Immunology, Immunotherapy (August 02, 2017): 10.1007/s00262-017-2047-2.
Varghese RS, Zuo Y, Zhao Y, Zhang Y, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM. "Protein Network Construction Using Reverse Phase Protein Array Data." Methods, 124 (July 2017): 89-99. 10.1016/j.ymeth.2017.06.017.
Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. "Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice." Cancer Immunol Immunother (2017): 10.1007/s00262-017-2077-9.
Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. "RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells." BIO-PROTOCOL, 7, 15 (2017): 10.21769/BioProtoc.2435.
Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C. "Yes-associated Protein Mediates Immune Reprogramming In Pancreatic Ductal Adenocarcinoma." Oncogene, 36, 9 (March 02, 2017): 1232-1244. 10.1038/onc.2016.288.
Berens EB, Sharif GM, Schmidt MO, Yan G, Shuptrine CW, Weiner LM, Glasgow E, Riegel AT, Wellstein A. "Keratin-associated Protein 5-5 Controls Cytoskeletal Function And Cancer Cell Vascular Invasion." Oncogene, 36, 5 (February 02, 2017): 593-605. 10.1038/onc.2016.234.
Ajina R, Aldeghaither D, Jablonski S, Weiner LM. "Cancer Immunotherapy." Comprehensive Medicinal Chemistry Iii (2017): 32-65. 10.1016/B978-0-12-409547- 2.12426-6.
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
PMID: 27924752
Bhuvaneshwar K, Belouali A, Singh V, Johnson RM, Song L, Alaoui A, Harris MA, Clarke R, Weiner LM, Gusev Y, Madhavan S. "G-doc Plus – An Integrative Bioinformatics Platform For Precision Medicine." Bmc Bioinformatics, 17, 1 (December 2016): 10.1186/s12859-016-1010-0.
Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I. "Screening Of Conditionally Reprogrammed Patient-derived Carcinoma Cells Identifies Ercc3-myc Interactions As A Target In Pancreatic Cancer." Clinical Cancer Research, 22, 24 (December 15, 2016): 6153-6163. 10.1158/1078-0432.CCR-16-0149.
Varghese R, Zuo Y, Zhao Y, Zhang YW, Jablonski S, Peirobon M, Petricoin E, Ressom H, Weiner L. "Network-based analysis of reverse phase protein array data." IEEE BIBM (August 2016).
Zhang Y-W, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, Golemis EA, Weiner LM. "Acquisition Of Estrogen Independence Induces Tob1-related Mechanisms Supporting Breast Cancer Cell Proliferation." Oncogene, 35, 13 (March 31, 2016): 1643-1656.10.1038/onc.2015.226.
Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR. "Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer." Oncol Lett (March 11, 2016): 1645-1650.
Weiner LM. "Voices." Oncology Times, 38, 3 (February 2016): 22-23. 10.1097/01.COT.0000480922.63827.56.
Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR. "Phase Ii Study Of Lapatinib And Capecitabine In Second-line Treatment For Metastatic Pancreatic Cancer." Cancer Chemotherapy And Pharmacology, 76, 6 (December 2015): 1309-1314. 10.1007/s00280- 015-2855-z.
Redman JM, Hill EM, Aldeghaither D, Weiner LM. "Mechanisms Of Action Of Therapeutic Antibodies For Cancer." Molecular Immunology, 67, 2 (October 2015): 28-45.10.1016/j.molimm.2015.04.002.
von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, CohenRB. "Phase I Study Of The Safety And Pharmacokinetics Of Trabectedin With Docetaxel In Patients With Advanced Malignancies." Cancer Chemotherapy And Pharmacology, 75, 5 (May 2015): 1047-1055. 10.1007/s00280-015-2705-z.
Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan TM, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD. "Synergistic Innate And Adaptive Immune Response To Combination Immunotherapy With Anti-tumor Antigen Antibodies And Extended Serum Half-life Il-2." Cancer Cell, 27, 4 (April 2015): 489-501. 10.1016/j.ccell.2015.03.004.
Aldeghaither D, Smaglo BG, Weiner LM. "Beyond Peptides And Mabs-current Status And Future Perspectives For Biotherapeutics With Novel Constructs." The Journal Of Clinical Pharmacology, 55, S3 (March 2015): S4-S20. 10.1002/jcph.407.
Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son D-S, Park HW, Yoo H-S, Song Y-J, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, Song PH, Kim K-A, Weiner LM. "Synthetic Lethal Screening Reveals Fgfr As One Of The Combinatorial Targets To Overcome Resistance To Met-targeted Therapy." Oncogene, 34, 9 (February 26, 2015): 1083-1093. 10.1038/onc.2014.51.
von Mehren M., Hudes G, Bookman M, Meropol MJ, Weiner LM, Sherman E, Li J, Bayever E, Cohen RB. "Phase 1 Study of the Safety and Pharmacokinetics of Trabectedin in Combination With Docetaxel in Patients With Advanced Malignancies." Cancer. (2015).
Murray JC, Aldeghaither D, Nasto RE, Jablonski SA, Tang Y, Weiner LM. "c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity." Cancer Immunology Research, 12 (December 02, 2014): 1186-98.
Surana R, Wang S, Xu W, Jablonski, SA, Weiner LM. "IL-4 Limits the Efficacy of Tumor-Targeted Antibody Therapy in a Murine Model." Cancer Immunology Research, 11 (November 02, 2014).
Smaglo BG, Aldeghaither D, Weiner LM. "The Development Of Immunoconjugates For Targeted Cancer Therapy." Nature Reviews Clinical Oncology, 11, 11 (September 30, 2014): 637-648. 10.1038/nrclinonc.2014.159.
Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. "A Phase Ii Trial Of The Proteasome Inhibitor Bortezomib In Patients With Advanced Biliary Tract Cancers." Clinical Colorectal Cancer, 13, 2 (June 2014): 81-86.10.1016/j.clcc.2013.12.005.
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. "Cd16xcd33 Bispecific Killer Cell Engager (bike) Activates Nk Cells Against Primary Mds And Mdsc Cd33+ Targets." Blood, 123, 19 (May 08, 2014): 3016-3026. 10.1182/blood-2013-10-533398.
Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K. "Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma." Am J Clin Oncol (April 28, 2014).
Kim S, Rait A, Rubab F, Rao AK, Kiritsy MC, Pirollo KF, Wang S, Weiner LM, Chang EH. "The Clinical Potential Of Targeted Nanomedicine: Delivering To Cancer Stem-like Cells." Molecular Therapy, 22, 2 (February 2014): 278-291. 10.1038/mt.2013.231.
Shivapurkar N, Weiner LM, Marshall JL, Madhavan S, Deslattes Mays A, Juhl H, Wellstein A. "Recurrence Of Early Stage Colon Cancer Predicted By Expression Pattern Of Circulating Micrornas." Plos One, 9, 1 (January 06, 2014): e84686. 10.1371/journal.pone.0084686.
Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. "Heterodimeric Bispecific Single-Chain Variable – Fragment Antibodies Against EpCam and CD16 Induce Effective Antibody-Dependent Cellular Cytoxicity Against Human Carcinoma Cells." Cancer Biotherapy & Radiopharmaceuticals (April 2013).
Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams, GP, Weiner LM, Cheng JD. "Identification of inhibitory scFy antibodies targeting fibroblast activation protein utilizing phage display functional screens." FASEB Journal, 27, 2 (February 2013): 581-589.
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang D, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. "Targeting C4-demethylating Genes In The Cholesterol Pathway Sensitizes Cancer Cells To Egf Receptor Inhibitors Via Increased Egf Receptor Degradation."Cancer Discovery, 3, 1 (January 2013): 96-111. 10.1158/2159-8290.CD-12-0031.
Weiner LM, Wu C. "Egfr, Immunology." Cancer Therapeutic Targets (2013): 1-10. 10.1007/978-1-4614-6613-0_27-2.
Madhavan S, Gusev Y, Natarajan TG, Song L, Bhuvaneshwar K, Gauba R, Pandey A, Haddad BR, Goerlitz D, Cheema AK, Juhl H, Kallakury B, Marshall JL, Byers SW, Weiner LM. "Genome-wide Multi-omics Profiling Of Colorectal Cancer Identifies Immune Determinants Strongly Associated With Relapse." Frontiers In Genetics, 4 (2013): 10.3389/fgene.2013.00236.
Shuptrine CW, Surana R, Weiner LM. "Monoclonal Antibodies For The Treatment Of Cancer." Seminars In Cancer Biology, 22, 1 (February 2012): 3-13.10.1016/j.semcancer.2011.12.009.
Weiner LM, Murray JC, Shuptrine CW. "Antibody-based Immunotherapy Of Cancer: New Insights, New Targets." Cell (2012).
Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. "Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production." Molecular Cancer Therapeutics, 11, 12 (2012): 2674-2684.
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. "Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death." Oncogene, 31, 10 (2012): 1217-1227.
Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. "Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment." Cancer Immunology & Immunotherapy, 61, 1 (2012): 49-61.
Weiner LM, Astsaturov I. "Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation." Cancer Journal. (2012).
Weiner LM, Lotze MT. "Tumor-cell death, autophagy, and immunity." New England Journal of Medicine, 366, 12 (2012): 1156-1158.
Murray JC, Wu CS, Weiner LM. "Why Cetuximab Is Not Active In The Adjuvant Setting." Current Colorectal Cancer Reports, 7, 3 (September 2011): 211-217.10.1007/s11888-011-0103-4.
Clarke R, Shajahan AS, Wang Y, Tyson JJ, Riggins RB, Weiner LM, Bauman WT, Xuan J, Zhang B, Facey C, Aiyer H, Cook K, Hickman FE, Tavassoly I, Verdugo A, Chen C, Zwart A, Wärri A, Hilakivi-Clarke LA. "Endoplasmic Reticulum Stress, The Unfolded Protein Response, And Gene Network Modeling In Antiestrogen Resistant Breast Cancer." Hormone Molecular Biology And Clinical Investigation, 5, 1 (January 01, 2011): 10.1515/hmbci.2010.073.
Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, Weiner LM.. "A Systems Medicine Platform for Personalized Oncology." Neoplasia., 13, 9 (2011): 771-783.
Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R. "Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells." Nature Review of Cancer, 11, 7 (2011): 523-532.
Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, Marks JD, Adams GP.. "Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors." Cancer Research, 71 (2011): 2250-2259.
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. "Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma." American Journal of Clinical Oncology, 34, 1 (2011): 70-75.
Deeken JF, Weiner LM.. "Supportive Care for Oncology Treatment: Not Just Icing on the Cake.." Annals of Internal Medicine, 153, 6 (September 21, 2010): 411-2.
Weiner LM, Surana R, Wang S. "Monoclonal antibodies: versatile platforms for cancer immunotherapy." Nat Rev Immunol, 10, 5 (May 2010): 317-327.
Weiner LM, Surana R, Murray J.. "Vaccine Prevention of Cancer: Can Endogenous Antigens be Targeted?." Cancer Prevention Research., 4 (April 03, 2010): 410-5.
Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weine. "Synthetic lethal screen of an EGFR-centered network to improve targeted therapies." Science Signal, 3, 140 (2010): ra67.
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. "The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research." Clinical Cancer Research, 15, 17 (September 2009): 5323-5337.
Weiner LM, Dhodapkar MV, Ferrone S. "Monoclonal antibodies for cancer immunotherapy." Lancet, 373, 9668 (March 2009): 1033-1040.
Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. "Imunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma..."." Clinical Cancer Research, 15, 4 (2009): 1443-1451.
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. "Mechanisms of tumor resistance to EGFR-targeted therapies." Expert Opinion on Therapeutic Targets, 13, 3(2009): 339-362.